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Background: Adequate monitoring tools are required to optimise the immunosuppressive therapy of an individual
patient. Particularly, in calcineurin inhibitors, as critical dose drugs with a narrow therapeutic range, the optimal
monitoring strategies are discussed in terms of safety and efficacy. Nevertheless, no pharmacokinetic monitoring
markers reflect the biological activity of the drug. A new quantitative analysis of gene expression was employed to
directly measure the functional effects of calcineurin inhibition: the transcriptional activities of the nuclear factor of
activated T-cell (NFAT)-regulated genes in the peripheral blood.
Methods/Design: The CIS study is a randomised prospective controlled trial, comparing a ciclosporin A
(CsA)-based immunosuppressive regimen monitored by CsA trough levels to a CsA-based immunosuppressive
regimen monitored by residual NFAT-regulated gene expression. Pulse wave velocity as an accepted surrogate
marker of the cardiovascular risk is assessed in both study groups. Our hypothesis is that an individualised CsA therapy
monitored by residual NFAT-regulated gene expression results in a significantly lower cardiovascular risk compared to
CsA therapy monitored by CsA trough levels.
Discussion: There is a lack of evidence in individualising standard immunosuppression in renal allograft recipients.
The CIS study will consider the feasibility of individualised ciclosporin A immunosuppression by pharmacodynamic
monitoring and evaluate the opportunity to reduce cardiovascular risk while maintaining sufficient
immunosuppression.
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Current challenges for individualised immunosuppression
Calcineurin inhibitors (CNI) represent the most widely
used immunosuppressive agents in kidney transplantation.
More than 80% of all renal allograft recipients are on CNI
therapy [1]. Since the introduction of ciclosporin A (CsA)
in the early 1980s and tacrolimus (Tac) in the 1990s, acute
rejection rates have improved remarkably. The current
one-year survival rate of a renal allograft exceeds 90% [2].
In recent decades, the overall renal allograft survival has
not improved as expected, indicating a shift of graft failure
from early acute rejection to side effects of long-term
immunosuppression and chronic rejection. In addition,
death with a functioning graft is an important aspect in
the long-term follow-up after successful renal transplant-
ation. Cardiovascular (CV) disease is the leading cause of
death in kidney transplant recipients (KTRs), with a 3.5%
to 5% annual risk of fatal or non-fatal CV events, much
higher than in the general population despite adjustment
for traditional risk factors [3,4].
Undesirable side effects of CNIs, such as nephrotoxicity,
metabolic deterioration, aggravation of CV risk factors, as
well as the CNI contribution to the development of
chronic allograft dysfunction, have come into the focus
[5]. There are many efforts to reduce or withdraw CNIs in
order to decrease renal complications as well as other side
effects. However, insufficient immunosuppression with an
increased risk of rejection should be avoided [6,7].
In particular, the development of donor-specific anti-
bodies (DSA) and humoral rejection are the focus of recent
renal transplant research [8]. Concerning the avoidance of
relevant side effects, one of the investigational strategies is
to minimise CNIs combined with adequate mycophenolic
acid (MPA) exposure [9-11]. This strategy might result in
decreased cardiovascular risk, improved renal allograft
function and prolonged patient as well as allograft survival.
Adequate monitoring tools are required to optimise
the immunosuppressive therapy of an allograft recipient.
Particularly in CNIs, as critical dose drugs with a narrow
therapeutic range, optimal monitoring strategies are dis-
cussed in terms of safety and efficacy [12]. Nevertheless,
no pharmacokinetic (PK) monitoring markers reflect the
biological activity of the drug, namely suppression of
alloreactive immune responses.
Pharmacodynamic monitoring as a tool to optimise
immunosuppression
Detailed knowledge of the drug-specific mode of action is
required to establish and introduce a pharmacodynamic
(PD) monitoring assay. The proposed immunosuppressive
mode of CsA is the inhibition of the phosphatase activity
of calcineurin after binding of the corresponding CNI-
immunophilin complexes [13,14]. The main substrate of
calcineurin in T-cells is the phosphorylated transcriptionfactor ‘nuclear factor of activated T-cells’ (NFAT). NFAT
dephosphorylation by calcineurin is required for the nu-
clear translocation and subsequent transcriptional activa-
tion of several key genes of T-cell activation, such as
interleukin-2 (IL-2), tumour necrosis factor alpha (TNF-
α), and interferon gamma (IFN-γ) [15].
Recently, a new quantitative analysis of gene expression
was employed to measure directly the functional effects of
calcineurin inhibition: the transcriptional activities of
NFAT-regulated genes in the peripheral blood [16,17].
Several evaluations affirmed this approach as a useful tool
with the potential to individualise CNI therapy. A high
interindividual variability of residual NFAT-regulated gene
expression in patients with corresponding CsA or Tac doses
has been observed, which confirms various degrees of im-
munosuppression and T-cell activation. On the other hand,
intraindividual variability of residual NFAT-regulated gene
expression was low in repetitive measurements in one sin-
gle patient with a stable CNI dose. This pharmacodynamic
monitoring tool might have the potential for precise indi-
vidual dosing of CNIs [16,18,19].
To date, several evaluations and preliminary studies
have been published concerning residual NFAT-regulated
gene expression as a specific CNI monitoring tool in clin-
ical practice. NFAT-regulated gene expression in CsA
treatment has been evaluated in solid organ recipients,
such as kidney, liver and heart in adult and paediatric
patient cohorts [18-27]. All these studies show a cross-
sectional or prospective observational design, except for
one prospective interventional case-control study [19]. In
this study, 20 stable renal allograft recipients were
compared to 20 matched controls to analyse the feasibility
of stepwise adaption of CsA dosage by residual NFAT-
regulated gene expression. Tapering of CsA resulted in an
increase of residual NFAT-regulated gene expression from
6% (1 to 17) to 21% (7 to 32); and resulted in an improved
renal allograft function and blood pressure [19].
Comprehensive data on CsA monitoring by NFAT-
regulated gene expression are available, therefore, a pro-
spective randomised interventional trial was established
using CsA as a long-term worldwide-used immunosuppres-
sion. The Calcineurin Inhibitor-Sparing (CIS) trial is the
first randomised controlled study in stable renal allograft
recipients to evaluate this immunomonitoring method for
tapering of immunosuppression. The rationale and design
of the trial are introduced here.
Research aim and objectives
The CIS trial assesses for the first time in a randomised
prospective study, the improvement of the CV risk in
stable renal allograft recipients on a CsA regimen by
monitoring of standard CsA trough levels (C0s), com-
pared to the novel approach by residual NFAT-regulated
gene expression. It takes into account both the need to
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established immunosuppressive regimen.
Methods/Design
Study design
The CIS trial (RCHD-1004, protocol version 1.2, 23
December 2013) is a prospective, randomised, parallel-
grouped, confirmatory study (Figure 1). This trial is a
single-centre study performed at the Renal Clinic Heidelberg
(Department of Nephrology, University Hospital
Heidelberg). Stable renal allograft recipients on CsA treat-
ment are randomised, to be monitored and adapted either
by CsA C0s or residual expression of NFAT-regulated
genes. The study period is six months.
Selection of the primary endpoint
The primary objective of this trial is to show that a CsA-
based immunosuppressive regimen monitored by residual
NFAT-regulated gene expression results in a reduced CV
risk, compared to monitoring by standard CsA C0s in renal
allograft recipients. The CV risk is assessed by the change
of arterial stiffness measured by pulse wave velocity (PWV)
from baseline to Month 6.
The PWV is an established sensitive marker for the as-
sessment of CV risk, confirmed in a large number of
clinical studies including end-stage renal disease (ESRD)
population, older or transplanted patients [28,29]. In a
former study by our group, PWV was significantly lower
in renal allograft recipients with a CNI-free regimen in
comparison to CsA-treated patients [30].
Outcome measures
The change in the arterial stiffness assessed by PWV from
baseline (Visit 1) to Month 6 (Visit 3) is the primary effi-
cacy objective of the study. Carotid-femoral PWV pressureTarget CsA NFA
Target CsA C0 trou
Visit 1
Baseline + Randomization
1:1
Visit 2
Week 
Screening
Figure 1 Design of the Calcineurin Inhibitor-Sparing (CIS) trial. CsA, cias well as central blood pressure will be assessed using a
validated SphygmoCor device from AtCor Medical,
Sydney, Australia. The assessment of PWV is performed
blinded to drug treatment, results of CsA C0 or residual
NFAT-regulated gene expression. Measurement of PWV
as well as peripheral and central blood pressure is per-
formed at randomisation (Visit 1), Month 3 (Visit 3), and
Month 6 (Visit 4).
Secondary efficacy and safety objectives are given in
Table 1. One secondary objective of the CIS trial is to evalu-
ate the two treatment groups with respect to a composite
efficacy failure endpoint comprising biopsy-proven acute
rejection (BPAR), graft loss or death at the end of the study,
consistent with recommendations by the European Medi-
cines Agency (EMEA) [31]. Additional secondary objectives
include individual components of this composite failure
endpoint.
For the analysis of laboratory data, venous blood will be
drawn prior to medication intake and the blood probe will
be analysed in the centre’s local laboratory at each visit.
The renal function will be assessed by estimated glomeru-
lar filtration (EGF) rate, serum creatinine levels at each
study visit, cystatin C at baseline and end of study, and the
evolution of renal function (S-creatinine) over time by
slope analysis.
Safety objectives include standard assessments of adverse
events (AEs) and serious adverse events (SAEs), and spe-
cific objectives related to CV events such as hypertension,
hyperlipidaemia, and diabetes. In addition, at each study
visit, specific objectives that are of concern in renal allograft
recipients are assessed, including comorbidities such as ma-
lignancies, viral infections and CsA-induced side effects at
each study visit. Vital signs will be documented at each
study visit and a physical examination carried out at base-
line and end of study. In all suspected rejection episodes,T-RE 15-30% 
gh level 80 - 150 µg/L
4
Visit 3
Month 3
Visit 4
Month 6
Study Period
closporin; CNI, calcineurin inhibitor; MPA, mycophenolic acid.
Table 1 Objectives of the Calcineurin Inhibitor-Sparing (CIS) trial
Primary objective To evaluate a CsA-based immunosuppressive regimen monitored by residual NFAT-regulated gene
expression concerning reduction in cardiovascular risk assessed by the change in pulse wave velocity
from baseline to six-month follow-up, compared to a CsA-based regimen monitored by CsA trough
levels in renal allograft recipients
Secondary efficacy objectives To evaluate, in treatment group:
− a composite endpoint of biopsy-proven acute rejection (BPAR), graft loss, death and loss to follow-up
at Month 6
− Incidence of BPAR, graft loss, loss to follow-up or death at Month 6
− S-creatinine and cystatin C at Month 6.
− Renal allograft function (eGFR calculated by MDRD, Nankivell and Cockroft-Gault formulae) at Month 6
− Evolution of renal function (S-creatinine) over time by slope analysis
− Creatinine slope (1/serum creatinine versus time) including the treatment period between baseline and Month 6
Secondary safety objectives To evaluate, in treatment group:
− Incidence and severity of adverse events (AEs) and serious adverse events (SAEs)
− Incidence of AEs leading to discontinuation from the study
− Incidence of major cardiovascular events (myocardial infarction, apoplexy, peripheral arterial occlusive disease)
− Pulse wave velocity, aortic pulse pressure, aortic systolic pressure, aortic augmentation index, ejection
duration, heart rate variability
− Changes in blood pressure (central and peripheral pulse pressure, systolic and diastolic, mean arterial
blood pressure)
− Changes in antihypertensive medication (number of antihypertensives)
− Changes in lipids (cholesterol, LDL-, HDL-cholesterol, triglyceride) and lipid-lowering drugs
− Changes in glucose levels, HbA1c and antidiabetic therapy
− Changes in cardiovascular risk (for example Framingham score)
− Changes in CsA-induced side effects (for example hypertrichosis, gingival overgrowth)
− Incidence and severity of infections
− Incidence and severity of malignancies
− Changes in the quality of life assessed by the ESRD SCL™ questionnaire and SF12 questionnaire
Exploratory objectives To explore the incidence of DSA in treatment group, and in relation to acute rejection, in a subset of
patients at participating centres
BPAR, biopsy-proven acute rejection; CsA, ciclosporin A; DSA, donor-specific antibody; eGFR, estimated glomerular filtration rate; ESRD, end-stage renal disease;
HDL, high-density lipoprotein; LDL, low-density lipoprotein; MDRD, Modification of Diet in Renal Disease; SCL, symptom checklist; SF12, Short-Form 12.
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latest within 24 hours after the initiation of anti-rejection
therapy. Biopsies will be read and interpreted by an inde-
pendent pathologist blinded to drug treatment according to
the updated Banff criteria.
The allograft will be presumed to be lost on the day
the patient starts dialysis and is not able to subsequently
be removed from dialysis or if the patient undergoes a
graft nephrectomy.
Information will be captured at each study visit on CV
disease, including angina pectoris that leads to hospitalisa-
tion or to intervention, myocardial infarction (segment
elevation myocardial infarction (STEMI), non-STEMI),
stroke (defined as brain ischaemia due to thrombosis, em-
bolism, or systemic hypoperfusion) and peripheral arterial
occlusive disease. At baseline and end of study, the pa-
tients’ CV risk will be calculated using the Framingham
score [32].All patients will be screened for gingival hypertrophy
and hypertrichosis at baseline and end of study. Health-
related quality of life assessment will be collected by the
ESRD symptom checklist (SCL) questionnaire and Short-
Form 12 (SF-12) scale [33,34] at baseline and end of study.
Both questionnaires will be self-completed by the patients.
Exploratory objectives include evaluation of the in-
cidence of DSA in the treatment group. The clinical
significance of DSAs - specifically whether or not they
contribute to antibody-mediated rejection - is currently a
topic under discussion concerning optimising long-term
renal allograft function [35].
Residual NFAT-regulated gene expression will be
assessed at every visit in both treatment groups. This will
provide additional data on the optimal range of residual
NFAT-regulated gene expression in renal allograft recipi-
ents, even with respect to allograft function and rejection
risk.
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and visits is shown in Table 2.Study population
The study population comprises 55 stable adult renal allo-
graft recipients. The study has broad eligibility criteria and
enrols CsA-treated patients with stable renal allograft
function. Deceased as well as living donor recipients willTable 2 Schedule of enrolment, interventions, and assessmen
PHASE
Visit
Day
Month
ENROLMENT
Eligibility screen
Inclusion/exclusion
Randomisation (allocation)
INTERVENTIONS
Intervention A (control group): adaption of CsA according to CsA C0
Intervention B (investigational group): adaption of CsA according to NFAT-ex
ASSESSMENTS
Demography
General medical history
Transplantation information
Physical examination
Vital signs
Study medication check
Laboratory test:
Hematocrit/Biochemistry
basic program
extended program
Urinanalysis
CsA C0 and C2 levels
NFAT-regulated gene expression
Pulse wave velocity
Rejection episodes
Renal biopsy
Adverse events
Severe adverse events
Comments
Concomitant therapy
Immunosuppressive therapy
Framingham score
Quality of life assessment
C0, CsA trough level; C2, two-hour level; CsA, ciclosporin A; NFAT, nuclear factor ofbe included. The eligibility criteria exclude patients with
already significantly deteriorating renal allograft function
or a history of chronic active rejection. Specific key inclu-
sion and exclusion criteria are shown in Table 3.Patient selection, randomisation and study treatment
All renal allograft recipients of the outpatient clinic of the
Department of Nephrology, University Hospital Heidelberg,ts
STUDY PERIOD
Baseline Post-allocation End of study
1 2 3 4
0
1 ± 7d 3 ± 14d 6 ± 14d
x
x
x
x x x
pression x x x
x
x
x
x x
x x x x
x x x
x x
x x
x x
x x x x
x x x x
x x x
as necessary
as necessary
as necessary
as necessary
as necessary
as necessary
x x x x
x x
x x
activated T-cell.
Table 3 Key inclusion and exclusion criteria for the Calcineurin Inhibitor-Sparing (CIS) trial
Key inclusion criteria Key exclusion criteria
- Male or female patients ≥18 years old. - Patients with a history of acute rejection classified > BANFF II, chronic active
antibody-mediated rejection or chronic T-cell-mediated rejection.
- Recipients of deceased or living kidney transplants. - Patients with an EC-MPS dose of <720 mg/d (MMF <1000 mg/d) and
MPA-AUC <30 mg*h/L.
- Time after the last renal transplantation at least six months. - Patients with symptoms of significant somatic or mental illness. Inability to
cooperate or communicate with the investigator, who are unlikely to comply
with the study requirements, or who are unable to give informed consent.
- Stable renal allograft function, defined as S-creatinine ≤3.5
mg/dL and Δ S-creatinine ≤30% during the last three months.
- Females of childbearing potential who are planning to become pregnant, who
are pregnant or lactating, and/or who are unwilling to use effective means of
contraception, unless
- Patients who are willing and able to participate in the study
and from whom written informed consent has been obtained.
a. their career, lifestyle, or sexual orientation precludes intercourse with a male partner,
or
b. their partners have been sterilised by vasectomy or other means
- Evidence of drug or alcohol abuse
- Patients actively taking part in an interventional trial
AUC, area under the curve; EC-MPS, enteric-coated mycophenolate sodium; MMF, mycophenolate mofetil; MPA, mycophenolic acid.
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clusion criteria. Patients will be enrolled consecutively.
After informed consent has been signed, the patient partici-
pates in the study. Each patient is uniquely identified by a
patient number. The investigator dispenses the patient
numbers in chronological order.
Patients are randomised after providing written in-
formed consent in a 1:1 ratio by a web-based ran-
domisation tool using block randomisation with fixed
block lengths (Randomisation In Treatment Arms
(RITA) randomisation system (University of Lübeck,
Germany)). In patients assigned to the standard group
(control group), CsA is administered adapted to CsA
C0s of 80 to 150 μg/L. In patients assigned to the investiga-
tional group (NFAT group), CsA is administered adapted to
residual NFAT-regulated gene expression of 15 to 30%. For
safety reasons, CsA C0 should be ≥30 μg/L in all patients.
Patients should stay within the target trough blood
levels or residual NFAT-regulated gene expression
throughout the study. The adaption of CsA dosage starts
after randomization as soon as the results of CsA C0 (con-
trol group) or NFAT-regulated gene expression (NFAT
group) are available, and at subsequent visits, if necessary.
Dose adjustments are performed in the control group if
CsA whole blood levels are outside the target range of
CsA C0 80 to 150 g/L and in the NFAT group if NFAT-
regulated gene expression is outside the range of 15 to
30% at the time of study visits (baseline, Month 1, Month
3 and Month 6). Adaption of CsA dose will be performed
according to the regular clinical practice in approximately
20% steps. In the case of severe CNI toxicity, dose reduc-
tions below the target levels may be performed at the in-
vestigators’ discretion. If CsA is interrupted for safety-
related considerations for more than four consecutive
weeks or more than two episodes longer than two weeks,
the patient should be withdrawn from the study.Concomitant immunosuppression
The immunosuppressive regimen used in the study is
widely accepted in clinical practice. All patients receive
CsA and MPA therapy, with or without steroids. MPA is
administered in a standard dosage of enteric-coated
mycophenolate sodium (EC-MPS) (Myfortic™) 180 to
720 mg twice a day (BID) or mycophenolate mofetil
(MMF) (Cellcept™) 250 to 1,000 mg BID. MPA exposure
will be monitored if daily EC-MPS dose is below 720 mg/
d or if MMF dose is below 1,000 mg/d. In this case, PK
monitoring of EC-MPS will include MPA C0, C1, C2, C3,
C4 and C6; and MPA-area under the curve (AUC) will be
calculated according to Sommerer et al. [36]. PK monitor-
ing of MMF will include MPA C0, C0.5 and C2; and
MPA-AUC will be calculated according to the Fixed-Dose
Concentration-Controlled (FDCC) study [37]. Target
MPA-AUC for both drugs is 45 mg*h/L with a minimum
of 30 mg*h/L.
Corticosteroids are administered according to local
centre practice.
Roles and responsibilities
The CIS study was designed by a steering committee con-
sisting of nephrologists specialised in renal transplantation,
an immunologist and a statistician. The CIS study is an
investigator-initiated trial; the study sponsor is the Renal
Clinic Heidelberg, Germany (Department of Nephrology,
University Hospital Heidelberg, Germany). Regulatory
study approval is provided by the competent authority, the
‘German Regulatory Authority’ as well as by the local Ethics
Committee. The study is conducted by the investigators
and the local Study Centre at the Department of Nephrol-
ogy, University Hospital Heidelberg. Data management and
biometry will be provided by the Institute of Medical Biom-
etry and Informatics, University Heidelberg, Germany.
Pharmacovigilance and monitoring will be performed by
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University Heidelberg, Germany.
Ethical, regulatory and management considerations
The study protocol (version 1.2, 23 December 2013) has
received ethical and governance approvals by the German
Regulatory Authority (reference number 4038718) as
well as by the local Ethics Committee (Ethics Committee,
University Hospital Heidelberg, Germany; reference num-
ber AFmo-622/2012). The CIS study was registered in the
European Union Drug Regulating Authorities Clinical
Trials (EudraCT) database on 18 July 2011 (EudraCT
Identifier 2011-003547-21). The study protocol follows
the principles of good clinical practice (GCP) and the
study is performed in compliance with the Declaration of
Helsinki. Researchers collecting data will have appropriate
research permissions, where required. Written informed
consent will be taken from each participant prior to study
enrolment by an experienced investigator. All data will be
managed and stored with protection of data privacy.
Documentation as well as corrections, if necessary, will
be done in accordance with GCP guidelines. All protocol-
required information collected during the trial must be en-
tered in the case report form (CRF). The completed CRFs
will be sent to the Institute of Medical Biometry and
Informatics, University Heidelberg, Germany. Data assess-
ment will be performed twice by two independent persons
to avoid incorrect entries. The completeness, validity and
plausibility of data are examined by validating programs,
which thereby generate queries. The investigator or the des-
ignated representatives are obliged to clarify or explain the
queries. All changes from the original data are documented
on audit files. Data will be maintained using the statistical
SAS program, Version 9.0 or higher (SAS Institute Inc.,
Cary, NC, USA). Monitoring will be performed regularly by
the independent Clinical Study Centre, University Hospital
Heidelberg, to check the completeness of the contents of
records and the CRFs, the adherence to the protocol and to
GCP, the progress of enrolment, and to ensure that study
drug is being stored, dispensed, and accounted for accord-
ing to specifications. Patient insurance for compensation to
those who suffer harm from trial participation is provided.
Sample size calculation
The changes for PWV between baseline (Visit 1) and six-
month follow-up (Visit 3) are calculated and compared
between the groups. For the CsA standard group, the esti-
mated change in PWV is close to 0. It is further assumed
that the baseline values are similar for both groups. From
study reports by Bahous et al. [29] and Seckinger et al.
[30], the probable change from baseline to the six-month
follow-up in the CsA low-dose group is estimated as δ =
1.3 m/s. Since some patients are expected to reveal treat-
ment complications that might decrease the differencesbetween the two treatment groups, the expected abso-
lute effect considered for sample size calculation is δ =
1.2. The standard deviation is assumed to be σ = 1.5 ml/
min. Similar standard deviations have been reported by
Seckinger et al. [30] and Bahous et al. [29], in different
comparison scenarios. However, as the absolute effect was
conservatively estimated, the proposed assumptions are
likely to yield a sample size that is large enough. With α =
0.05 and 1-β = 80%, n = 26 patients per group are required
to demonstrate superior efficacy of the NFAT group com-
pared to the CsA standard group in PWV when using a
two-sided unpaired t test. Including a small drop-out rate
of 5%, this results in a total number of 55 patients.Statistical analysis
Statistical analyses will be performed by an independent
statistician. The aim of the study is to prove that the
CsA therapy monitored by residual NFAT-regulated
gene expression is superior to CsA therapy monitored
by CsA C0s, by testing the following hypotheses: the null
hypothesis is that the change in PWV between baseline
and Month 6 is the same in both treatment arms. The
alternative hypothesis is that the change in PWV be-
tween baseline and Month 6 is lower or higher in the
NFAT group than in the control group.
Analysis of covariance (ANCOVA) will be applied with
treatment, age, baseline PWV and eGFR as covariates.
The primary analysis will be performed on the
intention-to-treat (ITT) population. The treatment
groups will be compared, using least-square means de-
rived from the ANCOVA model. The two-sided sig-
nificance level is given by 0.05. Using an ANCOVA
model instead of the two-sided unpaired t test, which
was used for sample size calculation, increases the
strength of the study, as the adjustment for covariates
leads to a reduction in variance.
Missing values will be replaced by the ‘last observation
carried forward’ (LOCF) approach. All secondary vari-
ables will be analysed in an exploratory way. Event rates
will be estimated using the Kaplan-Meier method to
handle patients who discontinue the treatment prior to
suffering sufficiently from an event. The two groups will
be compared using the log-rank test. This procedure will
be applied for the BPAR, graft loss, death, as well as the
composite endpoint of treatment failure. The main ana-
lysis will be performed at the last patient’s last visit at
Month 6. No interim analyses or design adaptations are
planned.Reporting
The CIS trial results will be reported in concordance
with the Consolidated Standards of Reporting Trials
(CONSORT) checklist [38].
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There is the need to optimise treatment with a well-
established standard immunosuppressive, such as CNIs,
since there is a lack of new agents significantly improving
short- and long-term outcome in renal transplantation.
Monitoring of immunosuppression by the specific bio-
logical effect provides the opportunity for individualised
immunosuppression with potential benefit regarding pa-
tient morbidity and mortality, as well as long-term allograft
function.
The strength of the CIS trial is that this is the first pro-
spective randomised controlled trial exploring residual
NFAT-regulated gene expression as a novel approach for
the monitoring of CsA treatment, in comparison to the
standard monitoring by CsA C0. In addition, CsA peak
level will also be assessed as several transplant centres use
this monitoring technique. PK and PD analyses will be
performed uniquely of all enrolled patients, including con-
trols; drug dosages will be applied according to predefined
criteria. The feasibility of CsA treatment by monitoring of
NFAT-regulated gene expression will be assessed.
The present study includes stable renal allograft recipi-
ents - a population with a great need for the optimisation
of the immunosuppressive regimen with established drugs
in order to improve long-term allograft and patient sur-
vival. In this patient cohort in particular, it could be shown
that there is a high interindividual variability in residual
NFAT-regulated gene expression despite CsA C0s within
the normal range [18]. Reduction of CsA dosages guided
by monitoring of NFAT-regulated gene expression might
be possible in a majority of these patients [19]. In the CIS
study, the benefits of PD monitoring on cardiovascular
risk factors as well as the effects on renal allograft function
will be assessed in detail. In addition, signs for insufficient
immunosuppression will be carefully evaluated, including
the explorative evaluation of the incidence of DSA in the
treatment group.
Cardiovascular events are the main cause of morbidity
and mortality in the long-term outcome of renal allograft
recipients. They are also an important cause of death with
a functioning graft. Aortic stiffness assessed by PWV has
been proven as an independent predictive value for all-
cause and CV mortality, CV disease, fatal and non-fatal
coronary events and fatal strokes in patients with various
levels of CV risk [28]. PWV is accepted as a marker of tar-
get organ damage by national and international guidelines,
for example the European Society of Hypertension guide-
lines [39]. As shown in recent studies, aortic stiffness
assessed by PWV is also an independent risk factor of CV
events in the short- and long-term interval in renal allo-
graft recipients [40,41]. Future multi-centre studies
including a greater number of patients will be designed to
investigate the opportunity of NFAT monitoring with
respect to hard endpoints, such as a combined endpointconsisting of BPAR, graft loss, loss to follow-up, and death
as well as to other endpoints of interest, such as renal
function.
The limitation of the study is that it is a single-centre
study that includes 55 patients of one transplant centre.
However, patient number is defined based on careful
sample-size calculation including an adequate attrition
rate. It is anticipated that the present study will indicate
strategies to minimise patient attrition and missing data.
Larger longitudinal multi-centre studies on PD CsA
monitoring by residual NFAT-regulated gene expression
assessing renal outcome will be performed, including the
scientific and practical experiences of the CIS study.
Conclusions
In conclusion, administration of CsA according to the bio-
logical effect, the residual NFAT-regulated gene expression,
includes the opportunity to lower the CV risk and specific
CsA-induced side effects in renal allograft recipients while
maintaining adequate immunosuppression. The present
study investigates this novel approach and will provide
valuable information on the potential validity and feasibility
of this particular PD monitoring method.
Trial status
The study opened to recruitment in October 2013 and is
expected to be complete by June 2014.
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